NDAORALFOR SUSPENSION
Approved
Sep 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
ZITHROMAX (azithromycin) by Pfizer is drug. Approved for respiratory tract infection, pneumonia, hiv infection and 6 more indications. First approved in 1994.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZITHROMAX (azithromycin) is an oral macrolide antibiotic approved in 1994 used to treat respiratory tract infections, pneumonia, sexually transmitted infections, and opportunistic infections in HIV patients. It works by inhibiting bacterial protein synthesis to stop microbial growth. The drug has broad-spectrum activity against gram-positive and gram-negative bacteria, as well as atypical pathogens.
LOE Approaching
Product approaching loss of exclusivity with minimal team expansion expected; roles focused on defending market share against generics and repositioning for niche indications.
Mechanism of Action
drug. [see Microbiology ()]
Indications (9)
Worked on ZITHROMAX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.